4.5.0.0 Vul­ner­a­ble Pa­tients at the End of Life

For pa­tients re­ceiv­ing pal­lia­tive care and end-‍of-‍life care, the focus should be to avoid symp­toms and com­pli­ca­tions from glycemic man­age­ment. Thus, when organ fail­ure de­vel­ops, sev­er­al agents will have to be down­ti­trat­ed or dis­con­tin­ued. For the dying pa­tient, most agents for type 2 di­a­betes may be re­moved (27). There is, how­ev­er, no con­sen­sus for the man­age­ment of type 1 di­a­betes in this sce­nario (28). See END-‍OF-‍LIFE CARE below, for ad­di­tional in­for­ma­tion.